Galderma S.A. has acquired the global rights, assets and obligations related to Metvix and Metvixia as well as the exclusive right to develop new dermatology products based on Photocure’s patented substance MAL. The products are used when treating skin cancer.
The acquisition includes Photocure’s Nordic market- and sales organization for Metvix® and Aktilite®. Galderma S.A. now holds world-wide rights regarding Metvix® and Aktilite®. The purchase sum amounts to 51 million EUR.
Moll Wendén has mainly assisted on labor law related issues and has also coordinated the advice from the Nordic law firms Føyen, Dahl and Wasselius & Wist.